UPC_APP_43786/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Procedural & sub-applicationsCosts AssessmentsHamburg LDGenericWritten Phase

Overview Decisions Documents Timeline

Parties

Claimants

Samsung Bioepis NL B.V.

Reps: Elena Hennecke (Freshfields PartG mbB)

Respondents

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Reps: Andrea Ritter (Simmons & Simmons LLP)

Judges

Sabine Klepsch
Alima Zana
Stefan Schilling
Rudi Goedeweeck

Patents

EP3167888
EP 3167888

CPC codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sector: Organic Chemistry

Outcome

Costs only

Filed: Jul 26, 2024

First decided: Aug 1, 2025

Language: English

Hamburg Local Division (1 August 2025) issued a costs decision following the dismissal of Alexion Pharmaceuticals' provisional measures application against Samsung Bioepis. The court assessed Samsung Bioepis' recoverable litigation costs, disallowing the costs of two UK solicitors as disproportionate but allowing the costs of the private expert Prof. Kontermann and reasonable travel expenses.

Open on UPC Registry